| Objective To observe the safety and efficacy of intravenous infusion of zoledronic acid ( 5 mg/100 ml ) in the treatment of primary osteoporosis and type 2 diabetes combined with osteoporosis.Methods Forty-six patients with osteoporosis, who were treated in our hospital, were selected.Among all the patients, 25 patients were divided into primary osteoporosis group, and 21 patients were divided into type 2 diabetes combined with osteoporosis group.Physical examination was performed, and the body mass index ( BMI ) was calculated.Serum glucose was detected using glucose oxidase method.The bone mineral density ( BMD) of the lumbar vertebrae ( L2-L4 ) and the left femoral neck was detected using dual energy X-ray absorptiometry ( DXA) . All the patients were treated with intravenous infusion of zoledronic acid.The adverse effect was monitored.One year later, BMD was re-detected, and the change of BMD after the treatment was also observed.Results No significant difference of age, BMI, and BMD of the lumbar vertebrae and the left femoral neck between the two groups was observed (P>0.05).After the intravenous infusion of zoledronic acid, the adverse effect including fever, acratia, headache, arthralgia, and nausea was observed in both groups.Seven patients in type 2 diabetes combined with osteoporosis group showed a transient increase of blood glucose, but all the symptoms disappeared and blood glucose returned to normal in 3 days.After 1-year treatment with zoledronic acid, BMD of the lumbar vertebrae and the left femoral neck in primary osteoporosis group increased by 4.27% and 4.11%, respectively, which increased by 3.42% and 3.26% in type 2 diabetes combined with osteoporosis group, respectively.BMD in both groups was significant higher than that before the treatment (P<0.05), but no significant difference between two groups was observed (P>0.05).Conclusion Zoledronic acid can increase BMD in patients with osteoporosis.And it has a good efficacy for the patients with primary osteoporosis or type 2 diabetes combined with osteoporosis. |